Header Logo
Last Name

You can now add alternative names! Click here to add other names that you've published under.

Darin Jones

TitleAssociate Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPharmaceutical Science, College of Pharmacy
DivisionPharmaceutical Science
Address200 South Cedar
Mail Slot # 622
Little Rock AR 72202
ORCID ORCID Icon0000-0003-1581-3453 Additional info
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    P01CA092584     (JONES, DARIN)Sep 21, 2021 - Aug 31, 2026
    NIH/Nat. Cancer Institute - Pass Through: Lawrence Berkeley National Laboratory
    Structural Cell Biology of DNA Repair Machines Project 3 - PARP: PAR-dependent, phase-transitioned protein assemblies, and DNA repair.
    Role: Principal Investigator

    80NSSC21M0323     (CANNON, MARTIN)Aug 15, 2021 - Aug 14, 2024
    National Aeronautics & Space Administration - Pass Through: Arkansas Space Grant Consortium
    Preventing immune system dysregulation during deep-space missions by Tocofexol, a modified isomer of vitamin E - AA request
    Role: Principal Investigator

    R01CA200231     (JONES, DARIN)Sep 1, 2018 - Feb 28, 2021
    NIH/Nat. Cancer Institute - Pass Through: University of Texas Health Science Center at Houston
    Pharmacological Modulation of Poly (ADP-ribose) Metabolism
    Role: Principal Investigator

    R01GM047251     (JONES, DARIN)Aug 1, 2018 - Jul 31, 2022
    NIH/Nat. Inst. of General Medical Sciences - Pass Through: University of New Mexico
    Cellular Functions of Eukaryotic DNA Ligases
    Role: Principal Investigator

    R01CA200231     (AHMED, ZAMAL)Mar 7, 2016 - Feb 28, 2021
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse additional bibliographic sources
    The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Mery DE, Compadre AJ, Ord??ez PE, Selvik EJ, Morocho V, Contreras J, Malag?n O, Jones DE, Breen PJ, Balick MJ, Gaudio FG, Guzman ML, Compadre CM. Analysis of Plant-Plant Interactions Reveals the Presence of Potent Antileukemic Compounds. Molecules. 2022 May 04; 27(9). PMID: 35566279.
      View in: PubMed
    2. Moiani D, Link TM, Brosey CA, Katsonis P, Lichtarge O, Kim Y, Joachimiak A, Ma Z, Kim IK, Ahmed Z, Jones DE, Tsutakawa SE, Tainer JA. An efficient chemical screening method for structure-based inhibitors to nucleic acid enzymes targeting the DNA repair-replication interface and SARS CoV-2. Methods Enzymol. 2021; 661:407-431. PMID: 34776222.
      View in: PubMed
    3. Ye Z, Xu S, Shi Y, Bacolla A, Syed A, Moiani D, Tsai CL, Shen Q, Peng G, Leonard PG, Jones DE, Wang B, Tainer JA, Ahmed Z. GRB2 enforces homology-directed repair initiation by MRE11. Sci Adv. 2021 Aug; 7(32). PMID: 34348893.
      View in: PubMed
    4. Nguyen MT, Moiani D, Ahmed Z, Arvai AS, Namjoshi S, Shin DS, Fedorov Y, Selvik EJ, Jones DE, Pink J, Yan Y, Laverty DJ, Nagel ZD, Tainer JA, Gerson SL. An effective human uracil-DNA glycosylase inhibitor targets the open pre-catalytic active site conformation. Prog Biophys Mol Biol. 2021 08; 163:143-159. PMID: 33675849.
      View in: PubMed
    5. Brosey CA, Houl JH, Katsonis P, Balapiti-Modarage LPF, Bommagani S, Arvai A, Moiani D, Bacolla A, Link T, Warden LS, Lichtarge O, Jones DE, Ahmed Z, Tainer JA. Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors. Prog Biophys Mol Biol. 2021 08; 163:171-186. PMID: 33636189.
      View in: PubMed
    6. Ord??ez PE, Mery DE, Sharma KK, Nemu S, Reynolds WF, Enriquez RG, Burns DC, Malag?n O, Jones DE, Guzman ML, Compadre CM. Synthesis, Crystallography, and Anti-Leukemic Activity of the Amino Adducts of Dehydroleucodine. Molecules. 2020 Oct 20; 25(20). PMID: 33092263.
      View in: PubMed
    7. Houl JH, Ye Z, Brosey CA, Balapiti-Modarage LPF, Namjoshi S, Bacolla A, Laverty D, Walker BL, Pourfarjam Y, Warden LS, Babu Chinnam N, Moiani D, Stegeman RA, Chen MK, Hung MC, Nagel ZD, Ellenberger T, Kim IK, Jones DE, Ahmed Z, Tainer JA. Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death. Nat Commun. 2019 12 11; 10(1):5654. PMID: 31827085.
      View in: PubMed
    8. Howes TRL, Sallmyr A, Brooks R, Greco GE, Jones DE, Matsumoto Y, Tomkinson AE. Erratum to "Structure-activity relationships among DNA ligase inhibitors; characterization of a selective uncompetitive DNA ligase I inhibitor" [DNA Repair 60C (2017) 29-39]. DNA Repair (Amst). 2018 01; 61:99. PMID: 29273192.
      View in: PubMed
    9. Howes TRL, Sallmyr A, Brooks R, Greco GE, Jones DE, Matsumoto Y, Tomkinson AE. Structure-activity relationships among DNA ligase inhibitors: Characterization of a selective uncompetitive DNA ligase I inhibitor. DNA Repair (Amst). 2017 12; 60:29-39. PMID: 29078112.
      View in: PubMed
    10. Ord??ez PE, Sharma KK, Bystrom LM, Alas MA, Enriquez RG, Malag?n O, Jones DE, Guzman ML, Compadre CM. Dehydroleucodine, a Sesquiterpene Lactone from Gynoxys verrucosa, Demonstrates Cytotoxic Activity against Human Leukemia Cells. J Nat Prod. 2016 Apr 22; 79(4):691-6. PMID: 27057812.
      View in: PubMed
    11. Franco FM, Jones DE, Harris PK, Han Z, Wildman SA, Jarvis CM, Janetka JW. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets. Bioorg Med Chem. 2015 May 15; 23(10):2328-43. PMID: 25882520.
      View in: PubMed
    12. Han Z, Harris PK, Jones DE, Chugani R, Kim T, Agarwal M, Shen W, Wildman SA, Janetka JW. Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer. ACS Med Chem Lett. 2014 Nov 13; 5(11):1219-24. PMID: 25408834.
      View in: PubMed
    13. Arhancet GB, Walker DP, Metz S, Fobian YM, Heasley SE, Carter JS, Springer JR, Jones DE, Hayes MJ, Shaffer AF, Jerome GM, Baratta MT, Zweifel B, Moore WM, Masferrer JL, Vazquez ML. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation. Bioorg Med Chem Lett. 2013 Feb 15; 23(4):1114-9. PMID: 23260349.
      View in: PubMed
    14. Parlow JJ, Case BL, Dice TA, Fenton RL, Hayes MJ, Jones DE, Neumann WL, Wood RS, Lachance RM, Girard TJ, Nicholson NS, Clare M, Stegeman RA, Stevens AM, Stallings WC, Kurumbail RG, South MS. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex. J Med Chem. 2003 Sep 11; 46(19):4050-62. PMID: 12954058.
      View in: PubMed
    15. South MS, Case BL, Wood RS, Jones DE, Hayes MJ, Girard TJ, Lachance RM, Nicholson NS, Clare M, Stevens AM, Stegeman RA, Stallings WC, Kurumbail RG, Parlow JJ. Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex. Bioorg Med Chem Lett. 2003 Jul 21; 13(14):2319-25. PMID: 12824026.
      View in: PubMed
    16. Davis MO, Hata DJ, Johnson SA, Jones DE, Harmata MA, Evans ML, Walker JC, Smith DS. Cloning, sequence, and expression of a blood group B active recombinant alpha-D-galactosidase from pinto bean (Phaseolus vulgaris). Biochem Mol Biol Int. 1997 Jul; 42(3):453-67. PMID: 9247703.
      View in: PubMed
    Jones's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description